Manufacturing Challenges and Rational Formulation Development for AAV Viral Vectors-Reference-Cited by-同舟云学术

Manufacturing Challenges and Rational Formulation Development for AAV Viral Vectors

Published:2021-07 Issue:7 Volume:110 Page:2609-2624
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Srivastava Arvind,Mallela Krishna M.G.,Deorkar Nandkumar,Brophy Ger

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference191 articles.

1. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure. the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b);Greenberg;JACC Hear Fail,2014

2. Pharmaceutical development of AAV-based gene therapy products for the eye;Rodrigues;Pharm Res,2019

3. Adeno-Associated Virus Vectors: Design and Delivery;Castle,2019

4. Chemical modification of the adeno-associated virus capsid to improve gene delivery;Mével;Chem Sci,2020

5. LUXTURNA(R). Prescription information; 2018. Available at:https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna. Accessed April 26, 2021.

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Roadmap for Drug Product Development and Manufacturing of Biologics;Journal of Pharmaceutical Sciences;2024-02

2. Deciphering the role of nanocarrier-based nucleic acid delivery to the brain for the management of neurodegenerative disorders;Journal of Drug Delivery Science and Technology;2024-02

3. Rational downstream development for adeno-associated virus full/empty capsid separation – A streamlined methodology based on high-throughput screening and mechanistic modeling;Journal of Chromatography A;2024-02

4. Nucleic Acid Delivery Nanotechnologies for In Vivo Cell Programming;ACS Applied Bio Materials;2024-01-30

5. Proof-of-concept for multiple AON delivery by a single U7snRNA vector to restore splicing defects in ABCA4;Molecular Therapy;2024-01